CLINICAL TRIALS PROFILE FOR ERGOCALCIFEROL
✉ Email this page to a colleague
All Clinical Trials for ERGOCALCIFEROL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00114556 ↗ | The Effect of Zoledronic Acid on Bone Density in Liver Transplant Patients | Completed | Novartis | Phase 4 | 2000-02-01 | Following liver transplantation, rapid bone loss occurs, particularly within the first 6 months post-transplant. This may be associated with fractures, most notable vertebral. The ability to assess osteoporosis therapies in this system may provide useful information for osteoporosis management in general. Hypotheses: 1. That treatment with the bisphosphonate, zoledronate, at the time of liver transplantation and at 1 month post-transplantation will prevent the early transplant-related bone loss (measured by bone densitometry and biochemical bone markers at 3 months) seen in patients who are not treated with a bisphosphonate 2. That continuing treatment with zoledronate at 3 monthly intervals for a total duration of 12 months will result in further improvements in bone density beyond that seen at 3 months 3. That calcium and vitamin D (vit D) supplementation of liver transplant patients does not prevent marked bone loss following transplantation. |
| NCT00114556 ↗ | The Effect of Zoledronic Acid on Bone Density in Liver Transplant Patients | Completed | Royal Prince Alfred Hospital, Sydney, Australia | Phase 4 | 2000-02-01 | Following liver transplantation, rapid bone loss occurs, particularly within the first 6 months post-transplant. This may be associated with fractures, most notable vertebral. The ability to assess osteoporosis therapies in this system may provide useful information for osteoporosis management in general. Hypotheses: 1. That treatment with the bisphosphonate, zoledronate, at the time of liver transplantation and at 1 month post-transplantation will prevent the early transplant-related bone loss (measured by bone densitometry and biochemical bone markers at 3 months) seen in patients who are not treated with a bisphosphonate 2. That continuing treatment with zoledronate at 3 monthly intervals for a total duration of 12 months will result in further improvements in bone density beyond that seen at 3 months 3. That calcium and vitamin D (vit D) supplementation of liver transplant patients does not prevent marked bone loss following transplantation. |
| NCT00157066 ↗ | Effects of Vitamin D Supplementation on Antimycobacterial Immunity | Completed | Department of Clinical Biochemistry, Homerton Hospital, London E9 6SR, UK | N/A | 2002-12-01 | The purpose of this study is to determine how vitamin D supplementation (ergocalciferol) affects the immune response to mycobacterial infection. |
| NCT00157066 ↗ | Effects of Vitamin D Supplementation on Antimycobacterial Immunity | Completed | Environmental Health Department, London Borough of Newham, London E15 4SF, UK | N/A | 2002-12-01 | The purpose of this study is to determine how vitamin D supplementation (ergocalciferol) affects the immune response to mycobacterial infection. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ERGOCALCIFEROL
Condition Name
Clinical Trial Locations for ERGOCALCIFEROL
Trials by Country
Clinical Trial Progress for ERGOCALCIFEROL
Clinical Trial Phase
Clinical Trial Sponsors for ERGOCALCIFEROL
Sponsor Name
| Sponsor Name for ERGOCALCIFEROL | |
| Sponsor | Trials |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 5 |
| Massachusetts General Hospital | 3 |
| King Faisal Specialist Hospital & Research Center | 3 |
| [disabled in preview] | 3 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
